Spermosens Advances JUNO-Checked Generation 3 Fertility Diagnostic System Through Clinical Validation
Key Insights
Spermosens has completed development of its JUNO-Checked (search) Generation 3 system, featuring significantly shorter analysis times and more robust sensor design for high-volume clinical workflows.
The company has initiated clinical validation studies at the Reproductive Medicine Center (search) in Malmö, with seven patients successfully tested to date as of the study's start in April 2026.
The diagnostic system measures sperm-egg binding capacity to identify fertilization failures in couples with unexplained infertility where conventional semen analysis shows normal parameters.
Swedish biotechnology company Spermosens AB (search) has completed development of its JUNO-Checked (search) Generation 3 fertility diagnostic system and initiated clinical validation studies, marking a significant milestone in bringing advanced sperm function testing to the global fertility market. The company has successfully tested seven patients at the Reproductive Medicine Center (search) (RMC) in Malmö since the study began in April 2026.
Enhanced System Performance for Clinical Integration
The JUNO-Checked (search) Generation 3 system incorporates significant technical improvements designed specifically for clinical and laboratory environments. Key enhancements include substantially shorter analysis times and a more robust sensor design capable of supporting high-volume clinical workflows. These improvements are intended to reduce technical and operational risks for future commercial partners while enabling seamless integration into existing laboratory platforms.
The system's design focuses on compatibility with established laboratory environments, addressing the specific needs of clinics and laboratories to facilitate adoption in clinical practice. According to the company, these enhancements strengthen their position in discussions with potential commercial partners.
Clinical Validation Study Design
The ongoing clinical validation study at RMC Malmö targets couples undergoing standard IVF treatment due to unexplained infertility, specifically those whose semen samples are classified as normal through routine testing methods. Unlike conventional semen analysis, JUNO-Checked (search) measures the critical sperm-egg binding capacity necessary for fertilization.
The study aims to demonstrate that JUNO-Checked (search) provides additional diagnostic value by identifying sperm-related dysfunctions not detected by conventional methods. Patient recruitment has proceeded according to plan, with clinical routines progressing as expected and the Generation 3 system performing as intended in the clinical setting.
Commercial Strategy and Market Approach
Spermosens plans to bring JUNO-Checked (search) to market through licensing or co-development agreements with established companies rather than direct commercialization. This strategic approach is designed to reduce capital requirements and improve the likelihood of successful market introduction by leveraging established distribution networks and commercial expertise.
The company positions JUNO-Checked (search) to address the global fertility market, where improved functional testing is essential for supporting clinical decisions and improving treatment outcomes. The diagnostic system targets the significant population of couples facing unexplained infertility, where standard testing methods fail to identify underlying causes of fertilization failure.
Timeline and Next Steps
Study completion is expected by the end of 2026, with successful validation representing a key step toward registration and commercialization. The first weeks of patient recruitment and testing have confirmed that both patient enrollment and clinical routines are progressing according to the previously communicated timeline.
Dr. Tore Duvold, CEO of Spermosens, stated: "We have started the clinical validation study on schedule, and seven patients have already been tested successfully. This confirms that the study is running as planned and that the Generation 3 system performs well in a clinical setting. We remain on track to complete the study by the end of 2026 and continue our work toward commercial partnerships for JUNO-Checked (search)."
The company continues to collaborate with leading research institutions to deliver what it describes as transformative fertility diagnostics to the global market, with shares listed on the Spotlight Stock Market under the ticker SPERM.